CASE PRESENTATION {#s1}
=================

The patient was a 7-mo-old girl, product of a diamniotic--dichorionic twin pregnancy, and born at 34 wk gestation. She was small for gestational age, with a birth weight of 1.49 kg (\<3rd percentile). She was prenatally diagnosed with left congenital diaphragmatic hernia (CDH), aortic arch hypoplasia, small left-sided cardiac structures, and ventricular septal defect. Genetic amniocentesis documented a normal, 46, XX karyotype and normal chromosomal microarray. The family was counseled as to a poor likelihood for survival based on a heart--lung ratio of 0.86, but elected to carry the twin pregnancy. She required significant respiratory and inotropic support postbirth but was able to undergo CDH repair on day of life (DOL) 5. At 3 mo of age she underwent aortic arch hypoplasia repair with ventricular septal defect closure. Her postoperative course was complicated by arrhythmias and acute hypotension leading to venoarterial (VA)-ECMO cannulation on postoperative day 1 (POD1). She was decannulated on POD4 and underwent delayed sternal closure on POD6. Her hospitalization was further complicated by eight culture-positive respiratory infections with Gram-positive and Gram-negative bacteria between her second week of life and death at 8 mo of age. She received multiple courses of antibiotics for suspected infection. She had feeding intolerance and underwent a Nissen Gastrostomy tube placement at 4 mo of age. Genetics consultation at 5 mo of age documented a delayed, dysmorphic, and hirsute infant with unusual penciled eyebrows, a medial eyebrow flare, anteverted nares, and posteriorly rotated ears, but well developed nails with no distal phalangeal hypoplasia ([Table 1](#MCS002469SWETB1){ref-type="table"}). A specific pattern of malformation was not recognized. A postnatal microarray was normal. Exome sequencing was suggested, but the funding was not approved. At 6 mo of age she underwent exploratory laparotomy for lysis of adhesions in the setting of a small bowel obstruction. There was no bowel loss. She was reintubated at 7 mo of age for respiratory failure. At that time she also developed atrial flutter requiring medical cardioversion with sotalol. She failed a trial of extubation and underwent a tracheostomy for procurement of a more stable airway. Sotalol was discontinued after 9 d of treatment in the setting of high-grade atrioventricular block. She had chronic lung disease (CLD), iatrogenic neonatal abstinence syndrome (NAS), persistent electrolyte derangements, and refractory metabolic alkalosis on diuretic therapy. The option for palliative care was presented on multiple occasions during the patient\'s hospitalization. Parental consensus on a decision could never be reached as one of the parents held out hope that advancements in technology would address most of the patient\'s health concerns in the absence of a confirmed diagnosis. Soon after referral for rapid whole-genome sequencing (rWGS), she developed another episode of respiratory failure requiring oscillatory ventilation. At the time of rWGS diagnosis she was found to be in septic shock requiring inotropic support with multiple agents. After meeting with genetic specialists to discuss the diagnosis and prognosis, the family opted for withdrawal of life support given the patient\'s critical condition and the fact that the underlying genetic condition could not be cured.

###### 

Phenotypic features of Coffin--Siris syndrome

  Feature                                                                                Proband (II-1)^a^   Relevance/alternate explanation
  -------------------------------------------------------------------------------------- ------------------- --------------------------------------------------------------
  Short stature                                                                          Yes                 Length \< 3% on WHO Girls (0--2 yr) gestation adjusted chart
  Coarse facies                                                                          Yes                 
  Facial hypertrichosis                                                                  Yes                 Chronic steroid administration
  Low-set ears/posteriorly rotated ears                                                  No                  
  Visual impairment/strabismus/downslanting palpebral fissures                           No                  
  Bushy eyebrows                                                                         No^b^               Patient with unusual eyebrow pattern but not bushy
  Long eyelashes                                                                         Yes                 
  Broad nasal tip                                                                        No^b^               
  Large mouth/thin upper lip vermilion/thick lower lip vermilion                         No^b^               
  Delayed dentition                                                                      No                  
  Frequent upper and lower respiratory tract infections (early life)                     Yes                 
  Feeding problems                                                                       Yes                 
  Skeletal anomalies including hypoplastic to absent terminal phalanges hands and feet   No^b^               
  Lumbosacral hirsutism/sparse scalp hair/hypertrichosis                                 Yes                 
  Delayed psychomotor development                                                        Yes                 
  Moderate to severe hypotonia                                                           Yes                 
  Seizures (in some patients)                                                            No                  
  Intellectual disability                                                                ND                  Unable to assess because of age
  Moderate to severe hypotonia                                                           Yes                 
  Hypoplastic corpus callosum (in some patients)                                         Yes                 
  Partial agenesis of corpus callosum (in some patients)                                 No                  

The list of clinical features is modified from the OMIM clinical synopsis (\#135900; CSS).

ND, not determined.

^a^None of these features were seen in the parents.

^b^Unusual feature.

The patient had an unaffected 7-yr-old brother and an unaffected twin brother. Her parents were both healthy. Her mother, age 37, identified as Hispanic and her father, age 42, as Caucasian Italian. Her mother had a history of a miscarriage at 3 mo gestation prior to this twin pregnancy. There was a maternal female cousin born with tricuspid atresia, who had required at least four surgeries.

TECHNICAL ANALYSIS AND METHODS {#s2}
==============================

The patient had a normal newborn screen, normal female karyotype (prenatal testing), and a normal female chromosomal microarray both prenatally (ARUP) and postnatally (Quest Diagnostics). rWGS became available during her seventh month of life.

One day after consent for trio rWGS, DNA was extracted and sequenced using an Illumina HiSeq X (Hudson Alpha) with paired 151-nt reads. The average library insert size was 369 nt for proband. Sequencing was completed 7 d after consent. Rapid alignment and nucleotide-variant calling was performed using the Dragen (Edico Genome) hardware and software ([@MCS002469SWEC12]). Yield was 195.5 Gb for the proband with a median coverage of 52× (51× coverage for genes annotated in Online Mendelian Inheritance in Man, OMIM) resulting in 4,945,287 distinct variant calls (4,059,083 single-nucleotide variants \[SNVs\], 886,204 small insertion deletion variants \[indels\], 27,343 coding domain \[CD\] variants, with a Ti/Tv ratio of 2.04) ([Supplemental Table S1](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a002469/-/DC1)). Variants were automatically annotated and analyzed in Opal Clinical (Omicia) ([@MCS002469SWEC3]). Initially, variants were filtered to retain those with allele frequencies of \<1% in the Exome Variant Server, 1000 Genomes Samples, and Exome Aggregation Consortium database ([@MCS002469SWEC8]; [@MCS002469SWEC9]). A differential diagnostic gene list was built in Phenolyzer ([@MCS002469SWEC21]) using the Human Phenotype Ontology (HPO) ([@MCS002469SWEC11]) and Systematized Nomenclature of Medicine-Clinical Terms (SNOMED-CT \[[@MCS002469SWEC16]\]) codes: Small for Gestational Age (HP:0001511), Congenital Diaphragmatic Hernia (HP:0000776), Congenital Heart Disease (HP:0030680), Coarctation of the Aorta (HP:0001680), Perimembranous Ventricular Septal Defect (HP:0011682), Mitral Stenosis (HP:0011570), Malrotation (HP:0002566), Failure to Thrive (HP:0001531), Hypoplasia of Corpus Callosum (HP:0002079), Asymmetric Hippocampal Bodies (L smaller than R), Dysmorphic Facial Features (HP:0001999), Long Eyelashes (HP:0000527), Flared Eyebrows (HP:0011229), Frontal Hirsutism (Hairy Forehead, HP:0011335), Anteverted Nose (HP:0000463), Low Nasal Bridge (HP:0005280), Hypotonia (HP:0008947), Thin Sparse Hair (HP:0008070), Developmental Delay (HP:0002194), and Frequent Respiratory Infections (HP:0002205), yielding 1678 genes. Variants were further filtered to retain those mapping to these 1678 genes using the differential diagnostic gene list built in Phenolyzer, yielding three variants of interest. Variants were assessed in accordance with ACMG variant classification criteria ([@MCS002469SWEC14]). Two variants were classified as variants of uncertain significance: c.422A\>C (p.Glu141Ala) in *NDUFAF4*, and c.685_686insCGC (p.Gln228_Gln229insPro) in *SMARCA2*. The *ARID1B* p.Lys1033Argfs\*32 was classified as likely pathogenic ([Supplemental Table S2](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a002469/-/DC1)) and was confirmed by Sanger Sequencing.

VARIANT INTERPRETATION {#s3}
======================

Interpretation of the rWGS results for this patient determined a de novo alteration in the AT-rich DNA interacting domain-containing protein 1B (*ARID1B*) gene, c.3096_3100delCAAAG (p.Lys1033ArgfsTer32), following genetic analysis of proband and both parents ([Table 2](#MCS002469SWETB2){ref-type="table"}). *ARID1B* is a component of a chromatin remodeling complex involved in cell cycle activation and is one of the genes that cause Coffin--Siris syndrome (CSS). CSS is a multisystem disease associated with congenital anomalies (congenital diaphragmatic hernia, spinal anomalies, and congenital heart defects), dysmorphic features, recurrent infections, and developmental delay. The prevalence of CSS has been estimated at \<1:100,000. Multiple genes have been implicated in this syndrome including *ARID1A, ARID1B, SMARCA2, SMARCA4, SMARCB1*, and *SMARCE1* ([@MCS002469SWEC18]). Inheritance is autosomal dominant. The major features of CSS are intellectual disability, speech delay, coarse facies, and hypertrichosis. Prevalent features are hypoplasia of the fifth digits/nails of hand/feet, feeding difficulties, and agenesis of the corpus callosum. Other more variable features include poor overall growth, craniofacial abnormalities, congenital diaphragmatic hernia, spinal anomalies, and congenital heart defects ([@MCS002469SWEC15]). The classic phenotype of CSS with hypoplastic distal phalanges and nails of the fifth fingers, the most distinct and objective of the classic features of CSS, is not always seen. As with many other conditions, the identification of the molecular basis of a specific condition has led to the expansion of the clinical phenotype, and features such as hypertrichosis, hypoplastic nails, or obvious coarse facial features have been found to be more subtle or absent in many cases. Others, such as hyperkeratosis, have only been recently recognized ([@MCS002469SWEC23]). More importantly, *ARID1B* is now recognized as one of the most frequent genes causing nonsyndromic intellectual disability ([@MCS002469SWEC15]).

###### 

Genomic findings

  Gene       Genomic location                        HGVS cDNA             HGVS protein         Zygosity       Parent of origin   Variant interpretation
  ---------- --------------------------------------- --------------------- -------------------- -------------- ------------------ ------------------------
  *ARID1B*   NM_020732.3: Chr 6:157495211GCAAAG\>G   c.3096_3100delCAAAG   p.Lys1033Argfs\*32   Heterozygous   De novo            Likely pathogenic

HGVS, Human Genome Variation Society.

The c.3096_3100delCAAAG (p.Lys1033ArgfsTer32) in *ARID1B* is a novel frameshift alteration leading to a premature termination codon. This deletion was not found in the 1000 Genomes, Exome Variant Server (EVS), or ExAC databases. Thus, it is presumed to be rare. Although this particular variant has not been reported in the literature, pathogenic alterations similar to this one have been reported ([@MCS002469SWEC7]). Based on the combined evidence, this variant is classified as likely pathogenic for CSS.

The incidence of CDH is 1 in 2000--5000 births ([@MCS002469SWEC1]), and it comprises 8% of all birth defects ([@MCS002469SWEC22]). It is the cause of 1%--2% of infant mortalities. CDH is caused by the incomplete formation of the diaphragm around the fourth to eighth week of gestation. Greater than 95% form posterior lateral (Bochdaleck) and ∼2% are anterior retrosternal or parasternal. Eighty-five percent of CDHs are on the left side of the body. Forty percent of CDH cases are associated with at least one additional anomaly like pulmonary hypoplasia, congenital heart disease, pulmonary hypertension, or other genetic anomalies ([@MCS002469SWEC22]).

More than 50 different genetic syndromes have been associated with CDH, ranging from aneuploidies (trisomy 18 is seen in 1%--2% of CDH), copy-number variations (tetrasomy 12p, 8p23.1 deletion, 15q26.1 deletion, 1q41-42 deletion, 8q23.1 deletion, 4p16 deletion, 11q23.2 deletion) ([@MCS002469SWEC20]; [@MCS002469SWEC17]), autosomal dominant disorders (*WT1*-opathies, Cornelia de Lange syndrome, Marfan syndrome, Kabuki syndrome), autosomal recessive disorders (Fryns syndrome), and X-linked disorders (craniofrontonasal syndrome, Simpson--Golabi--Behmel, focal dermal hypoplasia). Nonsyndromic single gene mutations (*GATA4*, *ZFPM2/FOG2*, *DIPS1*) have also been reported. The causes of 80% of CDH cases are still unknown and are thought to be multifactorial ([@MCS002469SWEC20]), although some genetic cases may not be detected by current testing strategies.

CDH is associated with a high rate of functional impairment. In a cross-sectional study of CDH repair survivors at Boston Children\'s Hospital, it was found that 66% had major medical issues at discharge, whereas 48% still had a current clinical problem on follow-up around 8 yr of age ([@MCS002469SWEC1]). Neonatal predictors of ongoing medical morbidity were prior ECMO use, presence of cardiac disease, and associated genetic abnormalities. Medical problems reported were related to vision, hearing, muscle weakness, speech, behavior, learning, eating, and breathing ([@MCS002469SWEC2]).

CDH is the most expensive noncardiac congenital anomaly. Based on the analysis of data obtained from approximately 200 hospitals in the United States (KID database; <https://www.hcup-us.ahrq.gov/kidoverview.jsp>) from 1997 to 2006, it is estimated that the national cost for management of surviving CDH patients is ∼\$158 million/yr. The national cost for management of all CDH patients (including the ones who do not survive to discharge) is \>\$250 million/yr. ECMO support is associated with a 2.4--3.5-fold increase in expenditure ([@MCS002469SWEC13]). [Figure 1](#MCS002469SWEF1){ref-type="fig"} shows the cumulative hospital costs at the time of the patient\'s death, which were \>\$1.8 million. The cost of rWGS at the time was \$8482 for a singleton and \$17,579 for a trio. The average cost of commercial WES including analysis is estimated at \$4000. At our institution WES is usually performed outpatient with a turnaround time of 6--8 wk because this test is not covered while inpatient. Hospital cost for taking care of this child if she were referred to us on DOL0, assuming a rWGS diagnosis on DOL14 (the results for this patient were available by day 7 of enrollment) and time of death of 6 d following approach of the family for withdrawal of life support (W/LS), would have been a little more than \$115,000. Literature review shows that the time from approach of families for W/LS to the child\'s death can range anywhere from 2--6 d depending on whether the patient is in the United States or Europe ([@MCS002469SWEC10]; [@MCS002469SWEC5]; [@MCS002469SWEC4]). The cost if referred on DOL4 would have been a little more than \$130,000. If we are willing to spend more than \$1.8 million attempting to improve the quality of life of these critically ill children, this case demonstrates that the cost of genomic sequencing should not be prohibitive to its implementation in their care.

![Cumulative hospital costs at the time of the patient\'s death, which was \>1.8 million dollars. Estimated cost of rapid whole-genome sequencing (rWGS) at the time patient was sequenced was \$8482 in a singleton and \$17,579 for a trio. Estimated cost of whole-exome sequencing (WES) with interpretation on average \$4000. Hospital cost for taking care of this child if she was referred to us on DOL0, assuming a diagnosis on DOL14 and time of death of 6 d post approach of families for W/LS, would have been a little more than \$115,000. The cost if referred on DOL4 would have been a little more than \$130,000. This figure illustrates that the cost of genomic sequencing would not have been prohibitive even if the patient had been referred for sequencing early in the course of her treatment.](MCS002469Swe_F1){#MCS002469SWEF1}

SUMMARY {#s4}
=======

CDH is the most expensive noncardiac congenital anomaly and is associated with significant long-term functional impairment. Genetic testing should be pursued early in the management of infants with CDH given myriad potential genetic etiologies. In this case rWGS allowed identification of a single gene disorder with long-term implications for outcome that assisted in the management of the patient. For this particular patient earlier diagnosis may have shortened the clinical course, obviating suffering for the patient and family and reducing expenditures for the health-care system.
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